🔎 Trials Near Me

Home › Diffuse Intrinsic Pontine Glioma › Colorado

Diffuse Intrinsic Pontine Glioma clinical trials in Colorado

8 studies for Diffuse Intrinsic Pontine Glioma are looking for participants at sites in Colorado.

Cities in Colorado

ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas

  • Children's Hospital Colorado, Aurora
RecruitingPhase 2
12 Months – 39 Years · All sexes · Updated Sep 21, 2026 · NCT06838676

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

  • Children's Hospital Colorado, Aurora
RecruitingPhase 1/2
12 Months – 21 Years · All sexes · Updated Sep 11, 2026 · NCT04870944

Targeted Pediatric High-Grade Glioma Therapy

  • Children's Hospital Colorado, Aurora
RecruitingObservational study
12 Months – 39 Years · All sexes · Updated Sep 8, 2026 · NCT05839379

Study of Olutasidenib and Temozolomide in HGG

  • Children's Hospital Colorado, Aurora
RecruitingPhase 2
Ages 12 to 39 · All sexes · Updated Sep 1, 2026 · NCT06161974

PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma

  • Children's Hospital Colorado, Aurora
RecruitingPhase 2
Ages 3 to 39 · All sexes · Updated Aug 24, 2026 · NCT05096481

Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

  • Children's Hospital Colorado, Aurora
RecruitingEarly phase 1Healthy volunteers welcome
Ages 1 to 21 · All sexes · Updated Jun 29, 2026 · NCT06333899

Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

  • Children's Hospital Colorado, Aurora
RecruitingPhase 2
12 Months – 39 Years · All sexes · Updated May 29, 2026 · NCT05843253

A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion

  • Children's Hospital Colorado, Aurora
RecruitingEarly phase 1
Up to age 21 · All sexes · Updated Mar 18, 2026 · NCT04655404

From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.